Bioventus, Inc., reported net sales at $137.1m in the second-quarter financial results of 2023, a decrease of 2.3% year-overyear.
The company reported adjusted earnings before taxes, depreciation, and amortization of $28,2 million, a 26.1% rise from the previous year period.
According to the press release, Bioventus sold its wound business in the second quarter 2023 and received $31 million as net proceeds to pay off debts and improve the financial position.
“We are pleased with our team’s strong execution in the second
